Shots:  

• Sosei Heptares to receive $5M as milestones triggered by the dosing of the first subject in a clinical trial. In Jun’2019- Pfizer nominated the candidate for advancement and granted $3M as milestones  
• The companies collaborated in 2015 to develop therapies directed at up to ten GPCR targets across multiple therapeutic areas. The collaboration has deployed Sosei Heptares' StaR technology and SBDD capabilities to design oral small molecules modulating different GPCR targets across Pfizer’s areas of interest
• Pfizer is responsible for developing and commercializing therapies for each target and has exclusive global rights to any resulting agents. This is the eighth GPCR-targeted drug candidate to enter clinical trials

­ Ref: PRNewswire | Image: Twitter